Skip to main content
NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.87%ABBV+0.39%CSCO-2.13%1398.HK-1.12%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.53%UNH-1.34%3988.HK+0.95%0005.HK+1.71%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.54%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.53%EURCAD-0.51%CADCHF+0.47%AUDJPY+0.45%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.38%GBPAUD-0.34%GBPHKD+0.32%USDZAR-0.30%GBPMXN-0.28%AUDUSD+0.28%EURNZD-0.28%GBPCAD-0.27%EURUSD-0.26%USDCAD-0.25%AUDNZD+0.25%NZDCHF+0.25%GBPZAR-0.24%EURGBP-0.23%NZDCAD-0.22%USDCHF+0.22%PLNJPY+0.20%EURZAR-0.20%NOKJPY+0.19%GBPCHF+0.19%SGDJPY+0.17%NZDJPY+0.16%USDILS+0.16%NZDMXN+0.16%AUDSGD+0.16%NZDSGD+0.15%EURJPY-0.15%USDJPY+0.14%USDSEK-0.13%AUDNOK+0.13%USDDKK-0.11%AUDDKK+0.10%EURHKD+0.10%USDPLN-0.10%USDCNH-0.10%GBPJPY+0.09%USDTHB+0.09%USDNOK-0.09%CHFJPY-0.09%CHFSGD+0.08%USDSGD-0.06%EURCHF-0.05%GBPNZD-0.05%USDMXN-0.05%EURSGD+0.05%CHFNOK+0.05%USDCOP-0.04%EURCZK+0.03%EURSEK-0.03%NZDUSD+0.03%GBPUSD-0.02%EURCNH+0.02%AUDCAD+0.01%EURNOK+0.01%EURDKK-0.01%USDHKD+0.01%CHFSEK0.00%EURPLN0.00%GBPSGD0.00%XPTUSD+2.04%XAGUSD+1.55%GAGUSD+1.55%HG1+1.37%GAUUSD+1.07%XAUUSD+1.07%UKOIL-0.92%USOIL-0.75%S1+0.70%COTTON+0.62%C1+0.40%XNGUSD+0.39%BTCUSD-1.13%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.10%DOGEUSD+5.25%XMRUSDT-2.54%LINKUSD+7.35%XLMUSD-2.87%BCHUSDT-6.99%LTCUSD+1.20%UNIUSD-7.02%SUIUSD-6.41%HBARUSDT-1.54%TONUSD+18.86%TAOUSDT-5.83%AAVEUSD-4.77%DOTUSDT+2.74%ICPUSDT-6.49%ONDOUSDT+1.05%WLDUSDT-6.00%JUPUSDT-2.00%ARBUSDT-4.85%ATOMUSDT+6.87%STXUSDT+6.69%INJUSDT-6.79%FETUSDT-3.86%PYTHUSDT+9.17%TIAUSDT+8.46%SEIUSDT-1.96%IMXUSDT+6.83%GRTUSDT-3.88%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.76%AXSUSDT-5.79%POLUSDT-2.89%FARTCOINUSDT+1.53%EOSUSDT-0.69%DYDXUSDT-0.45%GALAUSDT-4.69%ORDIUSDT-6.40%RONINUSDT-4.25%NOTUSDT-5.84%NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.87%ABBV+0.39%CSCO-2.13%1398.HK-1.12%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.53%UNH-1.34%3988.HK+0.95%0005.HK+1.71%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.54%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.53%EURCAD-0.51%CADCHF+0.47%AUDJPY+0.45%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.38%GBPAUD-0.34%GBPHKD+0.32%USDZAR-0.30%GBPMXN-0.28%AUDUSD+0.28%EURNZD-0.28%GBPCAD-0.27%EURUSD-0.26%USDCAD-0.25%AUDNZD+0.25%NZDCHF+0.25%GBPZAR-0.24%EURGBP-0.23%NZDCAD-0.22%USDCHF+0.22%PLNJPY+0.20%EURZAR-0.20%NOKJPY+0.19%GBPCHF+0.19%SGDJPY+0.17%NZDJPY+0.16%USDILS+0.16%NZDMXN+0.16%AUDSGD+0.16%NZDSGD+0.15%EURJPY-0.15%USDJPY+0.14%USDSEK-0.13%AUDNOK+0.13%USDDKK-0.11%AUDDKK+0.10%EURHKD+0.10%USDPLN-0.10%USDCNH-0.10%GBPJPY+0.09%USDTHB+0.09%USDNOK-0.09%CHFJPY-0.09%CHFSGD+0.08%USDSGD-0.06%EURCHF-0.05%GBPNZD-0.05%USDMXN-0.05%EURSGD+0.05%CHFNOK+0.05%USDCOP-0.04%EURCZK+0.03%EURSEK-0.03%NZDUSD+0.03%GBPUSD-0.02%EURCNH+0.02%AUDCAD+0.01%EURNOK+0.01%EURDKK-0.01%USDHKD+0.01%CHFSEK0.00%EURPLN0.00%GBPSGD0.00%XPTUSD+2.04%XAGUSD+1.55%GAGUSD+1.55%HG1+1.37%GAUUSD+1.07%XAUUSD+1.07%UKOIL-0.92%USOIL-0.75%S1+0.70%COTTON+0.62%C1+0.40%XNGUSD+0.39%BTCUSD-1.13%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.10%DOGEUSD+5.25%XMRUSDT-2.54%LINKUSD+7.35%XLMUSD-2.87%BCHUSDT-6.99%LTCUSD+1.20%UNIUSD-7.02%SUIUSD-6.41%HBARUSDT-1.54%TONUSD+18.86%TAOUSDT-5.83%AAVEUSD-4.77%DOTUSDT+2.74%ICPUSDT-6.49%ONDOUSDT+1.05%WLDUSDT-6.00%JUPUSDT-2.00%ARBUSDT-4.85%ATOMUSDT+6.87%STXUSDT+6.69%INJUSDT-6.79%FETUSDT-3.86%PYTHUSDT+9.17%TIAUSDT+8.46%SEIUSDT-1.96%IMXUSDT+6.83%GRTUSDT-3.88%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.76%AXSUSDT-5.79%POLUSDT-2.89%FARTCOINUSDT+1.53%EOSUSDT-0.69%DYDXUSDT-0.45%GALAUSDT-4.69%ORDIUSDT-6.40%RONINUSDT-4.25%NOTUSDT-5.84%
RE

REGENXBIO Inc. (RGNX)

NASDAQ • Healthcare

$8.09
+$0.49 (+6.4%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$7.47
Day Range$7.44 - $8.3
Avg. Volume (3M)1.5M
Market Cap$418.2M
52 Week Range
$5.46$16.19
Next EarningsIn 27 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$108M100%
Gross Profitminus cost of goods$106.9M99%
Operating Incomeminus R&D and overhead$29.2M27%
Net Incomeminus taxes and the rest$22.7M21%

In plain terms: out of every $100 in revenue, REGENXBIO Inc. keeps $21 as net profit.

Fundamentals & Financials

Revenue (TTM)
$174.4M
Net Income (TTM)
-$196.4M
EPS (TTM)
-$3.79
ROA (TTM)
-50.81%
Current Ratio
2.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-28.7%Q1 2026-$1.3
-26.5%Q2 2026-$1.72
+446.2%Q3 2026$0.43
Next

Nov 5

in 27 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

REGENXBIO Inc. (RGNX) reports earnings on November 5, 2026. Wall Street expects EPS of -$1.208 on revenue of $15.9 million. For trailing context, revenue grew +405.7% year over year last quarter. The company has beaten EPS in 3 of its 8 most recent quarters, with attention on updates that could shift revenue timing.

View full earnings history

About REGENXBIO Inc.

REGENXBIO Inc. is a NASDAQ-listed biotechnology company that develops gene therapy candidates designed to introduce genes into cells, with therapies intended to correct genetic deficiencies or prompt cells to produce therapeutic proteins or antibodies. The company generated $170.4 million in FY2025 revenue.

Name
REGENXBIO Inc.
CEO
Curran Simpson
Website
www.regenxbio.com
Industry
Healthcare
Year Founded
2008
Employees
371

Today's Snapshot

AI-generated

RGNX closed 6.5% above yesterday's close, while its sector was flat. Shares changed hands at about half as much again as its usual level. Regenxbio ended a revived patent fight with Penn, a university, over Sarepta’s gene therapy.

Trading Volume

Above 10d avg 1.6M

2.2M

vs S&P 500 Today

Strong Outperformance

+7.06%

Updated: October 8, 2026 at 20:26 UTC

RGNX Headlines

REGENXBIO maps 2026 gene therapy milestones

March 6, 2026

6 min read
View All News

Technical Indicators

2 Buy3 Neutral3 Sell
RGNX presents a neutral technical picture: short-term moving averages have improved but the stock remains below longer-term 50/100/200-day levels, so gains face structural resistance. Momentum readings are mixed — RSI and MACD hover near neutral while short momentum is mildly positive — and ADX is low, indicating limited trend conviction. On-balance volume shows accumulation and the price is above the classic pivot near 7.51, providing a modest support reference. Volatility is relatively elevated for the price. Technical takeaway: Neutral — short-term strength is offset by longer-term resistance.
All signals
  • EMA (5 indicators)$7.69 - $9.94
    Sell
  • RSI (14)48.97
    Neutral
  • Stochastic %K (14, 3, 3)48.03
    Neutral
  • MACD Level (12, 26)-0.41
    Neutral

Peers & Related Assets

PGENPrecigen, Inc.
$7.6+0.8%
MGTXMeiraGTx Holdings plc
$10.5-3.0%
SLDBSolid Biosciences Inc.
$6.82-0.4%
FDMT4D Molecular Therapeutics, Inc.
$12.7+0.9%
RCKTRocket Pharmaceuticals, Inc.
$2.63+3.5%
LXEOLexeo Therapeutics, Inc. Common Stock
$3.21-3.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.